Source: Arthritis & rheumatology. Unidade: FM
Subjects: ARTRITE REUMATOIDE JUVENIL, FÁRMACOS ANTIRREUMÁTICOS, INJEÇÃO
ABNT
I, Hermine Brunner et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis results from a phase III open-label study. Arthritis & rheumatology, v. 70, n. 7, p. 1144-1154, 2018Tradução . . Disponível em: https://doi.org/10.1002/art.40466. Acesso em: 18 ago. 2024.APA
I, H. B., Tzaribachev, N., Vega-cornejo, G., Louw, I., Berman, A., Penades, I. C., et al. (2018). Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis results from a phase III open-label study. Arthritis & rheumatology, 70( 7), 1144-1154. doi:10.1002/art.40466NLM
I HB, Tzaribachev N, Vega-cornejo G, Louw I, Berman A, Penades IC, Anton J, Avila-zapata F, Cuttica R, Silva CAA da. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis results from a phase III open-label study [Internet]. Arthritis & rheumatology. 2018 ; 70( 7): 1144-1154.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1002/art.40466Vancouver
I HB, Tzaribachev N, Vega-cornejo G, Louw I, Berman A, Penades IC, Anton J, Avila-zapata F, Cuttica R, Silva CAA da. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis results from a phase III open-label study [Internet]. Arthritis & rheumatology. 2018 ; 70( 7): 1144-1154.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1002/art.40466